NCT06030375View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics After Continuous Infusion of KAND567

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

February 17, 2020

Primary Completion Date

April 27, 2020

Study Completion Date

April 27, 2020

Conditions
Healthy
Interventions
DRUG

KAND567

Continuous intravenous infusion for 6 hours

OTHER

Placebo

Continuous intravenous infusion for 6 hours

Trial Locations (1)

20520

Clinical Research Services Turku (CRST), Turku

Sponsors

Lead Sponsor

Novakand Pharma AB
All Listed Sponsors
lead

Novakand Pharma AB

INDUSTRY